Communiqués Lunit Inc.

Actions

A328130

KR7328130000

Cours en clôture Korea S.E. Autres places de cotation 00:00:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
52 600 ^KRW	-2,41%		+2,94%	-35,78%

24/05	Lunit présentera 7 études à l'Asco 2024, dont des innovations Ai dans la quantification de Her2, et des modèles prédictifs multimodaux pour la réponse à l'immunothérapie.	CI
13/05	Lunit Inc (KOSDAQ:A328130) a finalisé l'acquisition de Volpara Health Technologies Limited (ASX:VHT) auprès de Harbour Asset Management Limited et d'autres.	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients	27/03	AQ
Lunit SCOPE AI Enhances Pathologist Concordance and Accuracy in HER2, ER, and PR Assessment, New Study in Breast Cancer Research	15/03	AQ
Lunit Presents Seven Study Results at ECR 2024, Showcasing AI's Robust Performance in Diverse Clinical Settings	29/02	AQ
New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy across Diverse Tumors, published in the JITC	19/02	AQ
Lunit INSIGHT CXR Excels in Long Nodule Detection, Exceptional Performance in Head-to-Head Study published in Radiology	18/01	AQ
Lunit to Acquire Volpara, Scheme Implementation Agreement Signed	15/12	AQ
Lunit Advances to Stage 2 of Australia s National Breast Cancer Screening Project	12/12	AQ
Lunit Secures $150 Million in Capital Increase	16/11	AQ
Lunit Nets FDA Nod for AI-Powered 3D Breast Tomosynthesis Solution, Lunit INSIGHT DBT	15/11	AQ
Lunit Participates in Saudi Vision 2030 Healthcare Sandbox, Accelerating Saudi Arabia's Healthcare Transformation	27/10/23	AQ
First Immunotherapy Success in TKI-Resistant Lung Cancer Setting Demonstrates Power of AI-driven Immune Phenotyping by Lunit SCOPE IO, newly published in JCO	25/10/23	AQ
New Study Demonstrates Lunit SCOPE IO's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes, Findings to be presented at the ESMO 2023	17/10/23	AQ
Lunit Backs the Potential of Tertiary Lymphoid Structures Analysis as an Emerging Biomarker for Lung Cancer Treatment to be presented at WCLC 2023	22/08/23	AQ
Lunit and the Japan National Cancer Center Hospital East Partner in AI Pathology to Advance Precision Oncology	31/05/23	AQ
Guardant Health introduces Guardant Galaxy suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery	01/02/23	AQ
Top Artificial Intelligence Trends Influencing the Future of Radiology	12/08/22	AQ
NVIDIA -Shifting Into High Gear: Lunit, Maker of FDA-Cleared AI for Cancer Analysis, Goes Public in Seoul	22/07/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Sécurisez et Augmentez la Performance de vos Investissements grâce à notre Équipe d'Experts à vos Côtés

Sécuriser mes Investissements

fermer